Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models

Acta Neurochirurgica, Supplementum

Volumn , Issue 95, 2005, Pages 403-406

  Hua, Y ^a   Tang, L L ^a   Fewel, M E ^a   Keep, R F ^a,b   Schallert, T ^a,c   Muraszko, K M ^a   Hoff, J T ^a   Xi, G H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

argatroban; brain edema; Glioma; neurological deficits; rats; thrombin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ARGATROBAN; PIPECOLIC ACID DERIVATIVE;

ANIMAL; ARTICLE; BRAIN; BRAIN EDEMA; BRAIN TUMOR; CELL PROLIFERATION; DRUG EFFECT; FISCHER 344 RAT; GLIOMA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MENTAL DISEASE; RAT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN EDEMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOMA; INJECTIONS, INTRAVENTRICULAR; MALE; MENTAL DISORDERS; PIPECOLIC ACIDS; RATS; RATS, INBRED F344; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85052609237     PISSN: 00651419     EISSN: None     Source Type: Book Series    
DOI: 10.1007/3-211-32318-X_82     Document Type: Conference Paper

References (19)

1. Cavanaugh KP, Gurwitz D, Cunningham DD, Bradshaw RA (1990) Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. J Neurochem 54:1735-1743
2. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264
3. Hua Y, Keep RF, Schallert T, Hoff JT, Xi G (2003) A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. Acta Neurochir (Wien) [Suppl] 86:503-506
4. Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G (2002) Behavioral tests after intracerebral hemorrhage in the rat. Stroke 33:2478-2484
5. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP, Jr (1997) Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Sem Thrombos Hemostas 23:503-516
6. Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF (2002) Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke 33:3012-3018
7. Maragoudakis ME, Tsopanoglou NE (2000) On the mechanism (s) of thrombin induced angiogenesis. Adv Exp Med Biol 476:47-55
8. McKeage K, Plosker GL (2001) Argatroban. Drugs 61:515-522
9. Medrano EE, Cafferata EG, Larcher F (1987) Role of thrombin in the proliferative response of T-47D mammary tumor cells. Mitogenic action and pleiotropic modifications induced together with epidermal growth factor and insulin. Exp Cell Res 172:354-364
10. Neveu I, Jehan F, Jandrot-Perrus M, Wion D, Brachet P (1993) Enhancement of the synthesis and secretion of nerve growth factor in primary cultures of glial cells by proteases: a possible involvement of thrombin. J Neurochem 60:858-867
11. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928
12. Ogiichi T, Hirashima Y, Nakamura S, Endo S, Kurimoto M, Takaku A (2000) Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neuro Oncol 46:1-9
13. Ornstein DL, Meehan KR, Zacharski LR (2002) The coagulation system as a target for the treatment of human gliomas. Sem Thromb Hemostas 28:19-28
14. Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124:58S-68S
15. Schallert T, Leasure JL, Kolb B (2000a) Experience-associated structural events, subependymal cellular proliferative activity, and functional recovery after injury to the central nervous system. J Cereb Blood Flow Metab 20:1513-1528
16. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000b) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777-787
17. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259:94-97
18. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, Nakata M, Kitajima I, Maruyama I (2002) The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. Int J Oncol 20:921-928
19. Zacharski LR, Ornstein DL (1998) Heparin and cancer. Thromb Haemostas 80:10-23